Unknown

Dataset Information

0

Efficacy and Safety of Tedizolid Phosphate versus Linezolid in a Randomized Phase 3 Trial in Patients with Acute Bacterial Skin and Skin Structure Infection.


ABSTRACT: Tedizolid phosphate is approved for the treatment of acute bacterial skin and skin structure infection (ABSSSI) caused by Gram-positive bacteria in the United States, Europe, and other countries. In this multicenter, double-blind, phase 3 study, 598 adult ABSSSI patients in China, Taiwan, the Philippines, and the United States were randomized to receive 200?mg of tedizolid, intravenously (i.v.)/orally (p.o.), once daily for 6?days or 600?mg of linezolid, i.v./p.o. twice daily for 10?days. The primary endpoint was early clinical response rate at 48 to 72?h. Secondary endpoints included programmatic and investigator-assessed outcomes at end-of-therapy (EOT) and posttherapy evaluation (PTE) visits. Safety was also evaluated. In the intent-to-treat (ITT) population, 75.3% of tedizolid-treated patients and 79.9% of linezolid-treated patients were early responders (treatment difference, -4.6%; 95% confidence interval [CI], -11.2, 2.2). After exclusion of patients who never received the study drug (tedizolid, n?=?8; linezolid, n?=?1; modified ITT), comparable early response rates were observed (tedizolid, 77.4%; linezolid, 80.1%; treatment difference, -2.7%; 95% CI, -9.4, 3.9). Secondary endpoints showed high and similar clinical success rates in the ITT and clinically evaluable (CE) populations at EOT and PTE visits (e.g., CE-PTE for tedizolid, 90.4%; for linezolid, 93.5%). Both drugs were well tolerated, and no death occurred. Eight patients experienced phlebitis with tedizolid while none did with linezolid; hence, drug-related treatment-emergent adverse events were reported in a slightly higher proportion in the tedizolid (20.9%) arm than in the linezolid arm (15.8%). The study demonstrated that tedizolid in a primarily Asian population was an efficacious and well-tolerated treatment option for ABSSSI patients. (This study has been registered at ClinicalTrials.gov under registration no. NCT02066402.).

SUBMITTER: Lv X 

PROVIDER: S-EPMC6591607 | biostudies-literature | 2019 Jul

REPOSITORIES: biostudies-literature

altmetric image

Publications

Efficacy and Safety of Tedizolid Phosphate versus Linezolid in a Randomized Phase 3 Trial in Patients with Acute Bacterial Skin and Skin Structure Infection.

Lv Xiaoju X   Alder Jeff J   Li Li L   O'Riordan William W   Rybak Michael J MJ   Ye Hui H   Zhang Ruiping R   Zhang Zhongqi Z   Zhu Xu X   Wilcox Mark H MH  

Antimicrobial agents and chemotherapy 20190624 7


Tedizolid phosphate is approved for the treatment of acute bacterial skin and skin structure infection (ABSSSI) caused by Gram-positive bacteria in the United States, Europe, and other countries. In this multicenter, double-blind, phase 3 study, 598 adult ABSSSI patients in China, Taiwan, the Philippines, and the United States were randomized to receive 200 mg of tedizolid, intravenously (i.v.)/orally (p.o.), once daily for 6 days or 600 mg of linezolid, i.v./p.o. twice daily for 10 days. The pr  ...[more]

Similar Datasets

| S-EPMC4335893 | biostudies-literature
| S-EPMC6249184 | biostudies-literature
| S-EPMC5404528 | biostudies-literature
| S-EPMC6392685 | biostudies-literature
| S-EPMC4249542 | biostudies-literature
| S-EPMC3622392 | biostudies-other
| S-EPMC4123804 | biostudies-other
| S-EPMC4411017 | biostudies-other
| S-EPMC6615724 | biostudies-literature
| S-EPMC8326538 | biostudies-literature